AstraZeneca PLC · LSE:AZN
AstraZeneca — Investor Presentation (2002)
11 slides from AstraZeneca's investor presentation, 2002
Slide 1: Concluding Remarks: The goal of the pharmaceutical industry
Concluding Remarks A Tom McKillop Chief Executive Officer The goal of the pharmaceutical industry Products to New Treat Science Disease b Hugely successful over 25+ years b Facing new challenges A Concluding Remarks: Tom McKillop 1
Slide 2: Conflicting pressures on the industry
Conflicting pressures on the industry Growth Drivers Growth Limiters b Ageing population b Cost containment b Unmet medical need b Regulatory hurdles b New science and b Pressure on life cycles technology b Social responsibility b Better informed patients b Increasing costs b Proof of “value in use”
Slide 3: Situation today / Winners and Losers
Situation today b Greater competition b Higher R&D and Sales & Marketing costs b Higher barriers to market entry b Fewer new products b Lower prices for products b Shortening product life cycles A Winners and Losers b The industry must adapt BUT b The basic proposition remains unchanged b The life b
Slide 4: AstraZeneca strategy: Focus on the core business
AstraZeneca strategy b Focus on the core business A Focus on the core business Avecia ies Antiseptics pecialt Astra S Purest AstraZeneca Prescription Pharmaceutical Zeneca Company cals c hemi Dental A g ro Syngenta A Concluding Remarks: Tom McKillop 4
Slide 5: Build commercial strength: US salesforce productivity
AstraZeneca strategy b Focus on the core business b Build commercial strength A Drive sales – US salesforce productivity b Calls per day +11% b Length of calls +9% b 1st-line manager ‘days in field’ +23% Source: Scott Levin, AstraZeneca A Concluding Remarks: Tom McKillop 5
Slide 6: Drive sales: increase in call quality
Drive sales Increase in call quality 2001 to 2002 - % of calls rated excellent or good 60% 2001 YTD August 2002 % of calls rated Excellent or Good 50% 40% 30% 20% 10% 0% S TH ER IA TT J A SK CK S TI J& BM C AC YE BO IZ G ER R NE VA PF M W AB M E AR O AZ N PH TR AS Source: Scott Levin, AstraZeneca A
Slide 7: Maintain No 1 in gastroenterology
AstraZeneca strategy b Focus on the core business b Build commercial strength b Product transformation ✦ Maintain No 1 in gastroenterology A Maintain No 1 in gastroenterology $m 1999 2000 2001 2002 Q3 99 MAT Q3 00 MAT Q3 01 MAT Q3 02 MAT Losec® / 5,753 6,054 6,015 4,975 Prilosec® Nexium® 0 4 308 1,6
Slide 8: Drive growth products
AstraZeneca strategy b Focus on the core business b Build commercial strength b Product transformation ✦ Maintain No 1 in gastroenterology ✦ Drive growth products A Drive growth products 3500 3000 2500 Faslodex® 2000 Symbicort® Arimidex® $m Zomig® 1500 Atacand® Casodex® Seroquel® 1000 500 0 Q3 00 MA
Slide 9: Secure flow of new products
AstraZeneca strategy b Focus on the core business b Build commercial strength b Product transformation b Secure flow of new products A Secure flow of new products b Deliver Iressa®, Crestor™ and Exanta™ b Creativity in Discovery b Test concepts early b Eliminate weak projects b Focus resources Effec
Slide 10: Portfolio transformation: 2004 and beyond
Portfolio transformation 100% Exanta™ 90% Crestor™ 80% Iressa® 70% Faslodex® Prilosec® 60% Zestril® Symbicort® Plendil® 50% Nolvadex® Nexium® 40% Casodex® 30% Arimidex® Zomig® 20% Seroquel® 10% Atacand® 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 00 00 00 00 01 01 01 01 02 02 02 Growth/Launch Expiry Base A
Slide 11: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements In order to utilise the “Safe Harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This presentation contains forward-looking statements with re